or Try an Advanced Search...

    Technical Analysis for BRNS - Barinthus Biotherapeutics plc

    Grade Last Price % Change Price Change
    C 1.43 -3.89% -0.06
    BRNS closed down 3.89 percent on Friday, November 1, 2024, on 32 percent of normal volume.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Flat
    Historical BRNS trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Stochastic Reached Overbought Strength -3.89%
    Outside Day Range Expansion -3.89%
    Wide Bands Range Expansion -3.89%
    Gapped Up Strength -3.89%
    Overbought Stochastic Strength -3.89%
    NR7 Range Contraction 0.14%
    NR7-2 Range Contraction 0.14%
    Narrow Range Bar Range Contraction 0.14%
    Older End-of-Day Signals for BRNS ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 24 hours ago
    Down 2 % about 24 hours ago
    Down 1% about 24 hours ago
    Gap Up Closed 2 days ago
    60 Minute Opening Range Breakout 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BRNS Chart by TradingView
    Basic chart:

    Profile

    Barinthus Biotherapeutics plc Description

    Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Immunotherapy Virotherapy Medical Research Carcinogens Papillomavirus HPV Immunotherapeutics Chronic Hbv Infection Human Papillomavirus Infection

    Is BRNS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 23 ChromaDex Leads The Charge With 2 Other US Penny Stocks To Watch
    Oct 1 Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
    Aug 8 Barinthus Biotherapeutics GAAP EPS of -$0.43 misses by $0.03
    Aug 8 Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
    Aug 1 Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
    Jun 6 Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
    May 13 Barinthus Biotherapeutics GAAP EPS of -$0.40
    May 13 Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
    May 4 Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)
    See more BRNS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.09
    52 Week Low 1.11
    Average Volume 34,172
    200-Day Moving Average 1.96
    50-Day Moving Average 1.27
    20-Day Moving Average 1.32
    10-Day Moving Average 1.43
    Average True Range 0.09
    RSI (14) 58.16
    ADX 31.46
    +DI 27.50
    -DI 8.07
    Chandelier Exit (Long, 3 ATRs) 1.26
    Chandelier Exit (Short, 3 ATRs) 1.41
    Upper Bollinger Bands 1.56
    Lower Bollinger Band 1.08
    Percent B (%b) 0.74
    BandWidth 36.62
    MACD Line 0.06
    MACD Signal Line 0.04
    MACD Histogram 0.0173
    Fundamentals Value
    Market Cap 55.28 Million
    Num Shares 38.6 Million
    EPS -1.45
    Price-to-Earnings (P/E) Ratio -0.99
    Price-to-Sales 13.61
    Price-to-Book 0.50
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.55
    Resistance 3 (R3) 1.57 1.54 1.53
    Resistance 2 (R2) 1.54 1.51 1.53 1.53
    Resistance 1 (R1) 1.48 1.49 1.47 1.47 1.52
    Pivot Point 1.46 1.46 1.45 1.45 1.46
    Support 1 (S1) 1.40 1.43 1.39 1.39 1.35
    Support 2 (S2) 1.38 1.41 1.37 1.34
    Support 3 (S3) 1.32 1.38 1.33
    Support 4 (S4) 1.31